Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Heart Lung and CirculationOpen Access

Established and Emerging Therapies for Cardiovascular-Kidney-Metabolic Syndrome: Harnessing the Benefits of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and Beyond

View Full Paper
Ask AI
Bookmark
Share

Authors

MAM. AllahwalaCMChinmay S. MaratheANAdam J. Nelson

Discussion

Loading...

Member takes

Overview

This review explores SGLT-2 inhibitors and GLP-1 receptor agonists, highlighting their efficacy in CKM syndrome.

Key Points

  • SGLT-2 inhibitors and GLP-1 receptor agonists improve outcomes in cardiovascular disease and chronic kidney disease.
  • Recent therapies have shown strong evidence for their benefits in managing type 2 diabetes and obesity.
  • Comparative analysis reveals distinct benefits of emerging therapies alongside established pharmacotherapies.
  • The increasing complexity of real-world applications raises considerations for effective treatment strategies.

Cite This Study

Allahwala et al. (2025) studied this question.

synapsesocial.com/papers/68c23c20b210217d64788802https://doi.org/10.1016/j.hlc.2025.07.005
View Full Paper
Ask AI
Bookmark
Share